



"تقييم الإصابة بفيروس الإبشتاين بار في المرضى المصريين المصابين بالالتهاب الكبدي الوبائي سي"

للحصول علي درجة الدكتوراه في الميكروبيولوجي

مقدمة من الطالب

محمد نبيل محمد إبراهيم

المدرس المساعد بقسم الميكروبيولوجي

تحت إشراف

ا.د/ اشرف عبده طبل

استاذ التكنولوجيا الطبية الحيوية

شعبة الهندسة الوراثية

بالمركز القومى للبحوث

ا.د/ سحر احمد حافظ شومان

استاذ الميكروبيولوجي

قسم الميكروبيولوجي

جامعة عين شمس

د/ حسام الدين احمد غانم

استاذ مساعد الميكروبيولوجي

قسم الميكروبيولوجي

جامعة عين شمس

قسم الميكروبيولوجي

كلية العلوم

جامعة عين شمس

(2014)



كلية العلوم
جامعة عين شمس

اسم الطالب : محمد نبيل محمد إبراهيم

الدرجة العلمية : ماجستير فى العلوم

القسم التابع له : الميكروبيولوجى

اسم الكلية : العلوم

الجامعة : عين شمس

سنة منح درجة الماجستير : 2011

سنة المنح درجة الدكتوراه : 2014



كلية العلوم
جامعة عين شمس

شكر و تقدير

أبدأ أولا واخرا بشكر الله عز و جل

ثم

كامل الشكر و التقدير و الإمتنان إلى السادة الأساتذة الذين قاموا
بالإشراف على هذا العمل:

ا.د/ سحر أحمد حافظ شومان

أستاذ الميكروبيولوجي - قسم الميكروبيولوجي - جامعة عين شمس

ا.د/ أشرف عبده طبل

أستاذ التكنولوجيا الطبية الحيوية - قسم التكنولوجيا الحيوية الميكروبية - بالمركز القومى للبحوث

د/ حسام الدين أحمد غانم

استاذ مساعد الميكروبيولوجي - قسم الميكروبيولوجي - جامعة عين شمس

كما أتقدم بالشكر إلى قسم الميكروبيولوجي - بكلية العلوم - جامعة

عين شمس.

ثم أتقدم بخالص الشكر إلى والدى ووالدتى وزوجتى واخوتى وإلى كل من
ساعدنى بالقول أو بالفعل أثناء قيامى بهذا العمل لإخراجه فى أحسن صورة.



إسم الطالب: محمد نبيل محمد إبراهيم

عنوان الرسالة: تقييم الإصابة بفيروس الإشتاين بار في المرضى المصريين المصابين
بالالتهاب الكبدي الوبائي سي

الدرجة العلمية: دكتوراه في علوم الميكروبيولوجي

لجنة الإشراف

أ.د/ سحر أحمد حافظ شومان

أستاذ الميكروبيولوجي- قسم الميكروبيولوجي- جامعة عين شمس

أ.د/ أشرف عبده طبل

أستاذ التكنولوجيا الطبية الحيوية- شعبة الهندسة الوراثية- بالمركز القومي للبحوث

د/ حسام الدين أحمد غانم

استاذ مساعد الميكروبيولوجي- قسم الميكروبيولوجي- جامعة عين شمس

لجنة التحكيم

أ.د. نبيلة أنور الشيخ

أستاذ المناعة – كلية الطب بنات – جامعة الأزهر

أ.د. محمد أحمد أحمد

أستاذ الفيروسات – المركز القومي للبحوث

أ.د. سحر أحمد حافظ شومان

أستاذ الفيروسات – قسم الميكروبيولوجي – كلية العلوم - جامعة عين شمس

الدراسات العليا

تاريخ المناقشة: / /

ختم الإجازة:

أجيزت الرسالة بتاريخ / /

موافقة مجلس الجامعة

موافقة مجلس الكلية

/ /

/ /

ACKNOWLEDGEMENT

*First and foremost, I feel always indebted to Allah, the
most beneficent and merciful*

*I would like to express my deep gratitude and thanks to my dear supervisor prof. Dr. **Sahar Ahmed Shoman**, Professor of Microbiology, Department of Microbiology, Ain shams university, for her help, encouragement, continuous advice and her expert supervision to complete this thesis to be valuable.*

*I gratefully and sincerely thank my dear supervisor prof. Dr. **Ashraf Abdu Tabll**. Professor of Medical Biotechnology, Microbial Biotechnology Department, National Research center, for his help, continuous support, valuable instructions and guidance from the start of the work. He always was patient, perfect in work organization. I am proud to be one of his students and I hope that he is satisfied with me.*

*I gratefully and sincerely thank my dear supervisor Dr. **Hussam El-Din Ahmed Ghanim**, Assistant Prof. of Microbiology, Department of Microbiology, Ain shams university, for his help, and follow up during the research period.*

Deep thanks TO MY FATHER, MOTHER AND My WIFE and to all members of Microbiology department and every one helped me.

A special thanks to my dear

*Prof. Dr. **Ahmed Barakat Barakat**, for his support,
encouragement, valuable advices and constant help.*

LIST OF FIGURES

Figure No.	Content	page
Fig.i	A simplified illustration of flow cytometry technique events	98
Fig.1	RT-nested PCR products of serum samples.	100
Fig.2	Nested PCR of EBV-DNA in serum samples.	106
Fig.3	EBV infection among the study groups.	115
Fig.4	The activity levels of ALT and AST liver enzymes in patient and control groups.	124
Fig.5	The activity levels of ALT and AST liver enzymes in cases of patient group	125
Fig.6	The activity levels of ALT and AST liver enzymes in cases of negative control group	126
Fig.7	The activity level of ALT and AST liver enzymes in cases of normal control group.	127
Fig.8	Serum levels of human IL-15 in the study groups.	130
Fig.9	Serum levels of human IL-15 in cases of the study groups.	131
Fig.10	Serum levels of human IL-15 among the three study groups	132
Fig.11	Serum levels of human IFN- γ in the study groups.	135
Fig.12	Serum levels of human IFN- γ in cases of the study groups.	136
Fig.13	Serum levels of human IFN- γ among the three study groups	137

List of Figures

Fig.14	Flow cytometry report of CD3 ⁺ cells	139
Fig.15	Flow cytometry report of CD4 ⁺ cells and CD19 ⁺ cells	139
Fig.16	Dot plot analysis of Normal control sample	141
Fig.17	Dot plot analysis of (HCV/EBV) infected sample	143
Fig.18	Percentage of CD3 ⁺ , CD4 ⁺ and CD19 ⁺ cells in patient and Normal control cases	145

LIST OF TABLES

Table No.	Contents	page
Table 1	Detection of HCV-IgG in the study population	101
Table 2	Detection of HCV-RNA in the study population	101
Table 3	Detection of HCV-IgG in HCV-RNA positive cases.	101
Table 4	Detection of EBV-IgG in positive HCV-RNA patient group	104
Table 5	Detection of EBV-IgM in positive HCV-RNA patient group	104
Table 6	Detection of EBV-DNA in positive HCV-RNA patient group.	104
Table 7	Percentage of EBV-IgG of EBV-DNA positive patient group	105
Table 8	Percentage of EBV-IgM of EBV-DNA positive patient group	105
Table 9	Percentage of EBV-IgG of EBV-DNA negative patient group	105
Table 10	Detection of EBV-IgG in Negative Control group	109
Table 11	Detection of EBV-IgM in Negative Control group	109
Table 12	Detection of EBV-DNA in Negative Control group	109
Table 13	Percentage of EBV-IgG of positive EBV-DNA negative control group	110
Table 14	Percentage of EBV-IgM of positive EBV-DNA negative control group	110
Table 15	Percentage of EBV-IgG of negative EBV-DNA negative control group	110
Table 16	Detection of EBV-IgG in Normal Control group	113
Table 17	Detection of EBV-IgM in Normal Control group	113
Table 18	Detection of EBV-DNA in Normal Control group	113
Table 19	Percentage of EBV-IgG of positive EBV-DNA Normal control group	114

List of Tables

Table 20	Percentage of EBV-IgM of positive EBV-DNA Normal control group	114
Table 21	Percentage of EBV-IgG of negative EBV-DNA Normal control group	114
Table 22	Percentage of EBV infection types among patient group	117
Table 23	Percentage of EBV infection types among negative control group	119
Table 24	Percentage of EBV infection types among normal control group	121
Table 25	Percentage of CD3 ⁺ , CD4 ⁺ and CD19 ⁺ cells among study cases	145

ABBREVIATIONS

AIDS	Acquired Immuno-deficiency Syndrome
ALT	Alanine Amino-Transferase
APC	Antigen presenting cells
AST	Aspartate Amino-Transferase
BL	Burkitt's Lymphoma
BSA	Bovine Serum Albumin
CHC	Chronic Hepatitis C
CMV	Cytomegalovirus
CTLs	Cytotoxic T-lymphocytes
DCs	Dendritic cells
DNA	Deoxyribonucleic acid
EBER	EBV-Encoded RNA
EBNA	EBV-nuclear antigen
EBV	Epstein Barr-Virus
EDTA	Ethylene Di-amine Tetra-acetic acid
EIA	Enzyme Immuno-assay
ELISA	Enzyme Linked Immuno-Sorbant Assay
ER	Endoplasmic Reticulum
ETR	End of treatment response
EVR	Early viral response
FHF	Fulminant hepatic Failure
FITC	Flourescein isothiocyanate
FS	Forward scatter
Gp	Glycoprotein
HCC	Hepatocellular carcinoma
HCV	Hepatitis C Virus
HD	Hodgkin Disease
HHV-6	Human Herpes Virus 6
HIV	Human Immuno-defficiency Virus
HL	Hodgkin's Lymphoma
HLA	Human Leucocytes Antigen
HRC	Hodgkin & Reed-Sternberg cells
HRP	Horse Raddish Peroxidase
HSV-1	Herpes simplex virus-1

HSV-2	Herpes simplex virus-2
IDU	Injection drug users
IFN- γ	Interferon-gamma
IL	Interleukin
IM	Infectious Mononucleosis
IRES	Internal Ribosome entry sites
ISR	Immune status ratio
LC	Liver cirrhosis
LDL	Low Density Lipoprotein
LMP	Latent membrane protein
MHC	Major Histocompatibility Complex
NC	Non-Coding region
NFK	Nuclear factor K
NHL	Non-Hodgkin lymphoma
NK	Natural Killer
NKT	Natural Killer T-cells
NPC	Nasopharyngeal carcinoma
NS	Non-Structure protein
OD	Optical Density
ORF	Open Reading Frame
PAT	Parenteral Anti-Schistosomal Therapy
PBL	Peripheral Blood Leucocytes
PBS	Phosphate Buffer Saline Solution
PCR	Polymerase Chain Reaction
PE	Phycoerythrin
PTLD	Post-transplant lympho-proliferative disease
RdRp	RNA dependent RNA polymerase
RNA	Ribonucleic acid
RT-PCR	Reverse Transcriptase Polymerase Chain reaction
RVR	Rapid Viral Response
SAP	Serum Amyloid P component
SS	Side scatter
SVR	Sustained Viral Response
TMB	Tetra-methyl benzidine
TNF	Tumor Necrosis Factor
VVI	Virus -Virus Interaction

VZV	Varicella Zoster virus
WHO	World Health Organization

CONTENTS

1. Introduction.....	1
2. Review of Literature.....	7
I Human Herpes Viruses.....	17
1. Epstein Barr Virus Infection.....	12
1.1 Epstein Barr Virus.....	12
1.1.1 Structure and Genome.....	14
1.1.2 Target Cells.....	15
1.1.3 Life Cycle.....	16
1.1.4 Latency.....	18
1.2 Epidemiology of EBV infection.....	21
1.2.1 Prevalence, geographic distribution.....	21
1.2.2 Transmission & Risk factor for EBV infection	22
1.3 Pathogenesis & Disease of EBV	23
1.3.1 Infection in the Normal host.....	25
1.3.2 Chronic Active EBV.....	26
1.3.3 Cancer in Humans.....	27
1.4 Management of EBV infection.....	31
1.4.1 Diagnosis of EBV infection.....	31
1.4.2 Prevention & Vaccination.....	34
1.4.3 Treatment of EBV infection	37
1.5 Host defense against EBV infection.....	39
II Hepatitis C Virus Infection.....	41
1. Hepatitis C Virus.....	42
1.1 Structure and Genome.....	42
1.2 Replication of HCV.....	43
1.3 Epidemiology of HCV Infection.....	45
1.3.1 Prevalence of HCV Infection.....	45
1.3.2 Distribution of HCV genotypes.....	46
1.3.3 Transmission of HCV.....	47
1.4 Life cycle of HCV.....	50
1.5 Management of HCV infection.....	52
1.5.1 Diagnosis.....	52
1.5.2 Treatment and vaccination.....	55
1.6 Immune response against HCV infection.....	58

III	Co-infection of EBV with other viruses.....	63
1.	With HIV.....	63
2.	With CMV.....	64
3.	With HCV.....	66
3.	Material and Methods	68
3.1	Study Population.....	68
3.2	Methods.....	68
2.1	Sample Collection.....	68
2.2	Serological analysis.....	69
2.1	Serological analysis of HCV infection.....	69
2.2	Serological analysis of EBV infection.....	73
2.2.1	Qualitative determination of EBV-IgM.....	73
2.2.2	Qualitative determination of EBV-IgG.....	76
2.3	Molecular analysis.....	78
3.1	HCV-RNA detection by RT-PCR.....	78
3.2	EBV-DNA detection by nested-PCR.....	80
3.3	Agarose gel electrophoresis.....	83
2.4	Biochemical analysis.....	84
2.5	Measurement of Cytokine levels.....	88
5.1	Measurement of serum levels of human IFN- γ	88
5.2	Measurement of serum levels of human IL-15.....	92
5.3	Measurement of CD+4, CD+3, and CD+19 percentages by using Flow cytometer instrument....	96
4.	Results.....	99
I.	Detection of HCV in the Study Population.....	99
A-	Detection of HCV-IgG antibodies in Serum samples.....	99
B-	Detection of HCV-RNA in Serum samples.....	99
II.	Detection of EBV antibodies and DNA in Patient group.....	102
A-	Detection of EBV-IgG antibodies in patient group.....	102
B-	Detection of EBV-IgM antibodies in patient group.....	102
C-	Detection of EBV-DNA in patient group.....	102
III	Detection of EBV antibodies and DNA in Negative Control group.....	107
A-	Detection of EBV-IgG antibodies in negative control group.....	107
B	Detection of EBV-IgM antibodies in negative control group.....	107
C-	Detection of EBV-DNA in negative control group.....	107
IV	Detection of EBV antibodies and DNA in Normal Control group.....	111
A-	Detection of EBV-IgG antibodies in negative control group.....	111
B-	Detection of EBV-IgM antibodies in negative control group.....	111

	C-	Detection of EBV-DNA in negative control group.....	111
V		Types of EBV infection among Study population.....	116
	A-	Types of EBV infection in patient group.....	116
	B-	Types of EBV infection in Negative control group.....	118
	C-	Types of EBV infection in Normal control group.....	120
VI		The changes in liver function enzymes (ALT&AST) activity levels among study population.....	122
	A-	ALT and AST activity levels in patient group.....	122
	B-	ALT and AST activity levels in negative control group.....	123
	C-	ALT and AST activity levels in normal control group.....	123
VII		Cytokines (IL-15 & IFN- γ) Levels in the serum of 3 study group....	128
	A.	Serum Levels of IL-15.....	128
	A.1	Serum Levels of IL-15 in patient group.....	128
	A.2	Serum Levels of IL-15 in Negative control group.....	128
	A.3	Serum Levels of IL-15 in Normal control group.....	129
	B-	Serum Levels of IFN- γ	133
	B.1	Serum Levels of IFN- γ in patient group.....	133
	B.2	Serum Levels of IFN- γ in Negative control group....	133
	B.3	Serum Levels of IFN- γ in Normal control group.....	134
VIII		Measurement of CD3 ⁺ , CD4 ⁺ and CD19 ⁺ cells percentage.....	138
	A-	Analysis of Normal control samples.....	140
	B-	Analysis of double infected samples (HCV/EBV samples).	142
5		Discussion	149
6		Conclusion	161
7		English Summary	163
8		References	166
9		Arabic Summary	1